BioSpace News Archive

Drug Development

Oxford Biomedica notes Axovant’s update on Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease

Axovant reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease.

March 11, 2019
·
2 min read
Business

Modus Therapeutics strengthens management team with appointment of Mats Blom, MBA as CFO

Mr Blom joins Modus Therapeutics on April 1 from dual-listed Zealand Pharma, where he was CFO from 2010.

March 11, 2019
·
3 min read
Biotech Bay

AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

AcelRx Pharmaceuticals, Inc. announced that management will be presenting at the Oppenheimer 29th Annual Healthcare Conference to be held March 19 – 20.

March 11, 2019
·
2 min read
Business

BIO Statement on President’s Proposed 2020 Budget

Biotechnology Innovation Organization President and CEO Jim Greenwood issued the following statement regarding President Trump’s FY 2020 budget proposal

March 11, 2019
·
2 min read
Business

Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer

BIOASIS TECHNOLOGIES INC. today announced that its board of directors has appointed Dr. Deborah A. Rathjen as president and chief executive officer.

March 11, 2019
·
3 min read
BioMidwest

Case Western Reserve University School of Medicine ranked No. 1 in Ohio, and No. 24 nationally, by U.S. News & World Report

Case Western Reserve University School of Medicine has been named the No. 1 research-oriented medical school in Ohio, according the influential annual ranking by U.S. News & World Report.

March 11, 2019
·
4 min read
Precision drugs could unmask cancers to the immune system and boost the effects of immunotherapy

- NHS-approved PARP inhibitor therapy found to boost the body’s immune response - Drugs could be used to increase number of patients who respond to immunotherapies - Treatment developed for ovarian and breast cancers could also work in some lung cancers

March 11, 2019
·
9 min read
Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline

The preclinical compound has been designated SL-1001 and is expected to enter the clinic in 2020.

March 11, 2019
·
6 min read
Business

ASLAN PHARMACEUTICALS SIGNS NEW AGREEMENT WITH BIOGENETICS FOR COMMERCIALISATION OF ASLAN003 IN SOUTH KOREA

ASLAN will grant BioGenetics exclusive rights to commercialise ASLAN003 in South Korea in exchange for an upfront payment of US$1 million and up to US$8 million in sales and development milestones.

March 11, 2019
·
6 min read
Business

Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs

Video webcast presentation at 9:00 a.m. GMT and additional conference call at 9:00 a.m. EDT.

March 11, 2019
·
23 min read